Immunomedics Inc (IMMU)

6.66
0.03 0.38
NASDAQ : Health Care
Prev Close 6.63
Open 6.98
Day Low/High 6.72 / 7.05
52 Wk Low/High 1.50 / 5.44
Volume 2.45M
Avg Volume 3.83M
Exchange NASDAQ
Shares Outstanding 106.08M
Market Cap 681.03M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Immunomedics Soars on Injunction Against Seattle Genetics Deal

Immunomedics Soars on Injunction Against Seattle Genetics Deal

The biotech company embattled by activist investor VenBio may not be able to go through with its licensing deal.

Activist VenBio Wins Control of Immunomedics Board

Activist VenBio Wins Control of Immunomedics Board

VenBio gained four seats on Immunomedics' board of directors.

Activist Investor Wins Control of Immunomedics Board Following Shareholder Vote

Activist Investor Wins Control of Immunomedics Board Following Shareholder Vote

The newly reconstituted Immunomedics board is likely to start a search for a new CEO and could either renegotiate the IMMU-132 deal with Seattle Genetics or cancel it.

Stockholders Endorse VenBio's Case For Meaningful Change At Immunomedics

Stockholders Endorse VenBio's Case For Meaningful Change At Immunomedics

venBio Select Advisor LLC ("venBio"), the beneficial owner of approximately 10.

VenBio Encourages Stockholders To Vote For Change

VenBio Encourages Stockholders To Vote For Change

venBio Select Advisor LLC ("venBio"), the beneficial owner of approximately 10.

First Week of April 21st Options Trading For Immunomedics

First Week of April 21st Options Trading For Immunomedics

Investors in Immunomedics, Inc. saw new options begin trading this week, for the April 21st expiration.

VenBio Sends Letter To Immunomedics Stockholders

VenBio Sends Letter To Immunomedics Stockholders

venBio Select Advisor LLC ("venBio"), the beneficial owner of approximately 10.

Immunomedics Comments On Baseless VenBio Lawsuit

Immunomedics Comments On Baseless VenBio Lawsuit

venBio's Lawsuit Underscores its Blatantly Self-Serving Agenda and Willingness to Potentially Destroy Stockholder Value for the Sake of Control

Activist Investor to Block Partnership of Immunomedics and Seattle Genetics

Activist Investor to Block Partnership of Immunomedics and Seattle Genetics

The largest shareholder of Immunomedics, VenBio, asks for an injunction against its partnership with Seattle Genetics.

VenBio Takes Steps To Protect Rights Of Immunomedics Stockholders

VenBio Takes Steps To Protect Rights Of Immunomedics Stockholders

venBio Select Advisor LLC ("venBio"), the beneficial owner of approximately 10.

Activist Investor Seeks Legal Block of Immunomedics Cancer Drug Partnership With Seattle Genetics

Activist Investor Seeks Legal Block of Immunomedics Cancer Drug Partnership With Seattle Genetics

VenBio accuses Immunomedics management of undervaluing and essentially giving away the cancer drug IMMU-132 because they were afraid of losing their jobs in a proxy vote.

Chesapeake Energy, Priceline, Schlumberger, ZELTIQ : 'Mad Money' Lightning Round

Chesapeake Energy, Priceline, Schlumberger, ZELTIQ : 'Mad Money' Lightning Round

Jim Cramer's bullish on ZELTIQ Aesthetics, Chesapeake Energy, Priceline Group and more.

Why These Market Gains Are More Powerful Than Trump: Cramer's 'Mad Money' Recap (Monday 2/13/17)

Why These Market Gains Are More Powerful Than Trump: Cramer's 'Mad Money' Recap (Monday 2/13/17)

Jim Cramer says it's a sea change: It's not just about economic growth, it's about global growth without inflation.

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Sage Therapeutics, Immunomedics and Myriad Genetics were among the premarket biotech stock movers on Monday.

VenBio Comments On Immunomedics Partnership Announcement

VenBio Comments On Immunomedics Partnership Announcement

venBio Select Advisor LLC ("venBio"), the beneficial owner of approximately 10.

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

The companies inked a $250 million deal on Friday that could be worth up to $2 billion, thanks to milestone payments.

Immunomedics Announces Postponement Of 2016 Annual Meeting

Immunomedics Announces Postponement Of 2016 Annual Meeting

New Meeting Date Provides Time for Modified "Go-Shop" Period Negotiated in Global Licensing Agreement of IMMU-132 with Seattle Genetics to Have Expired or Otherwise Been Completed and Allows Stockholders to Carefully Consider the Significant Value Created by the Licensing Transaction

Immunomedics Enters Into Exclusive Global Licensing Agreement With Seattle Genetics For Sacituzumab Govitecan (IMMU-132) With Potential Payments Of Up To Approximately $2 Billion, Plus Royalties

Immunomedics Enters Into Exclusive Global Licensing Agreement With Seattle Genetics For Sacituzumab Govitecan (IMMU-132) With Potential Payments Of Up To Approximately $2 Billion, Plus Royalties

Immunomedics to Receive $250 Million in Upfront Cash Payment; Plus Among Other Milestone Payments, an Additional $50 Million or Negotiated Economic Splits Relating to Rights Outside US, Canada and EU